Back

Interleukin-6 and suPAR improves prediction of all-cause mortality in type 1 diabetes - the Thousand & 1 Study

31 August 2024 (11:21 - 11:33)
Organised by: Logo
Congress Presentation Part of: Obesity and diabetes: risk assessment and prognosis Diabetes and the Heart ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hashmat Sayed Zohori Bahrami

Steno Diabetes Center, Copenhagen, Herlev (Denmark)

4 More presentations in this session

Presentation thumbnail
Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study
Doctor M. Lassen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Cardiovascular disease risk in people with diabetes in the era of universal diabetes screening
Miss J. Liang (Auckland, NZ)
Abstract Slides Video
Presentation thumbnail
Prognostic outcomes of masld and obesity in acute myocardial infarction
Doctor G. Kong (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Glucose lowering drugs with proven cardiovascular benefit following acute coronary syndrome in type 2 diabetes: treatment gaps and outcomes
Doctor I. Naoum (Haifa, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity and diabetes: risk assessment and prognosis
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 11:21 CET
You may be interested in
thumbnail
Congress Presentation
Inflammatory biomarkers suPAR, IL-6, and hsCRP and 13-year risk of mortality and MACE in type 2 diabetes: a prospective cohort study
thumbnail
Congress Session
Obesity and diabetes: risk assessment and prognosis
thumbnail
Congress Presentation
Interleukin-6 and cardiovascular prognosis in apparently healthy individuals

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources